drugset / Trial / NCT03251339
Safety and Immunogenicity of MSB11455 in Healthy Participants
RandomizedParallel-groupDouble-blindOther
Summary
The primary purpose of this study is to compare the immunogenicity and safety of MSB11455 and Neulasta in healthy adult participants.
Timeline
- Start
- 2017-08-21
- Primary completion
- 2018-02-05
- Completion
- 2018-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSB11455 | Unknown | 6 mg | Subcutaneous |
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
Indications
No indication recorded.